Literature DB >> 26959558

Individualized conditioning regimes in cord blood transplantation: Towards improved and predictable safety and efficacy.

R Admiraal1,2, J J Boelens1,2.   

Abstract

INTRODUCTION: The conditioning regimen used in cord blood transplantation (CBT) may significantly impact the outcomes. Variable pharmacokinetics (PK) of drugs used may further influence outcome. Individualized dosing takes inter-patient differences in PK into account, tailoring drug dose for each individual patient in order to reach optimal exposure. Dose individualization may result in a better predictable regimen in terms of safety and efficacy, including timely T cell reconstitution, which may result in improved survival chances. AREAS COVERED: Conditioning regimens used in CBT varies significantly between and within centres. For busulfan, individualized dosing with therapeutic drug monitoring has resulted in better outcomes. Anti-thymocyte globulin (ATG), used to prevent rejection and GvHD, significantly hampers early T-cell reconstitution (IR). Timely IR is crucial in preventing viral reactivations and relapse. By individudalizing ATG, IR is better predicted and may prevent morbidity and mortality. EXPERT OPINION: Individualization of agents used in the conditioning regimen in CBT has proven its added value. Further fine-tuning, including new drugs and/or comprehensive models for all drugs, may result in better predictable conditioning regimens. A predictable conditioning regimen is also of interest/importance when studying adjuvant therapies, including immunotherapies (e.g. cellular vaccines or engineered T-cell) in a harmonized clinical trial design setting.

Entities:  

Keywords:  Cord blood; PK/PD; hematopoietic cell transplantation; individualized dosing

Mesh:

Year:  2016        PMID: 26959558     DOI: 10.1517/14712598.2016.1164688

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  5 in total

Review 1.  Consensus recommendations for the role and competencies of the EBMT clinical pharmacist and clinical pharmacologist involved in hematopoietic stem cell transplantation.

Authors:  Claudia Langebrake; Rick Admiraal; Erik van Maarseveen; Agnès Bonnin; Tiene Bauters
Journal:  Bone Marrow Transplant       Date:  2019-05-17       Impact factor: 5.483

2.  ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint.

Authors:  Natasha Kekre; Joseph H Antin
Journal:  Blood Adv       Date:  2017-03-28

3.  Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes.

Authors:  J B Langenhorst; C van Kesteren; E M van Maarseveen; T P C Dorlo; S Nierkens; C A Lindemans; M A de Witte; A van Rhenen; R Raijmakers; M Bierings; J Kuball; A D R Huitema; J J Boelens
Journal:  Blood Adv       Date:  2019-07-23

4.  Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells.

Authors:  Robin L Williams; Sarah Cooley; Veronika Bachanova; Bruce R Blazar; Daniel J Weisdorf; Jeffrey S Miller; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2017-11-29       Impact factor: 5.742

5.  Therapeutic Drug Monitoring of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation: A Pilot Single-Center Study in Taiwan.

Authors:  Rong-Long Chen; Li-Hua Fang; Xin-Yi Yang; Mohsin El Amrani; Esther Veronique Uijtendaal; Yen-Fu Chen; Wei-Chi Ku
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.